Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for COVID-19 Olfactory Dysfunction
NCT05445921Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mepivacaine in anosmia, Hyposmia, parosmia and 1 more, sponsored by Washington University School of Medicine. Primary endpoint: Clinical Global Impression - Improvement at 1 month. Started Sep 2022; status: completed.
02
Drugs
mepivacaine
03
Conditions
anosmiaHyposmiaparosmiaOlfactory disorder
Beyond the preview
Go deeper on NCT05445921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445921.